Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Advertisement

Close

AACR Journals
For Authors
About Us
Article Collections
COVID-19
Webinars

header search

search input Search input auto suggest

Search

Advanced Search

Menu

About
Articles
First Disclosures
For Authors
Alerts
News
COVID-19
Webinars

Skip Nav Destination

Current Issue

Volume 21,

Issue 9

1 September 2022

View This Issue

About the Journal

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.. Read More About the Journal

Editor-in-Chief

Beverly A Teicher

View Full Editorial Board

Impact Factor

6.009

SUBMIT TO JOURNAL

Featured Articles

YES1: A Novel Therapeutic Target and Biomarker in Cancer

Irati Garmendia, et al.

LARGE MOLECULE THERAPEUTICS

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Andrea T. Hooper, et al.

SMALL MOLECULE THERAPEUTICS

PH-Binding Motif in PAR₄ Oncogene: From Molecular Mechanism to Drug Design

Jeetendra Kumar Nag, et al.

Trending - Altmetric

An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Last mentioned on Friday September 30 2022

PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design

Last mentioned on Thursday September 29 2022

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Last mentioned on Friday September 30 2022

Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells

Last mentioned on Friday September 30 2022

Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative Rhabdomyosarcoma

Last mentioned on Thursday September 29 2022

Latest
Most Read
Most Cited

Neoadjuvant radiation therapy and surgery improves metastasis-free survival over surgery alone in a primary mouse model of soft-tissue sarcoma

Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative Rhabdomyosarcoma

Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HER2pos cancer

Tumor Infiltrating Myeloid Cells Confer de novo Resistance to PD-L1 Blockade through EMT-stromal and Tgf-beta Dependent Mechanisms.

Tweets by MCT_AACR

Issues
Online First
News

Twitter

Online ISSN 1538-8514
Print ISSN 1535-7163

AACR Journals

Blood Cancer Discovery
Cancer Discovery
Cancer Epidemiology, Biomarkers, & Prevention
Cancer Immunology Research
Cancer Prevention Research
Cancer Research
Cancer Research Communications
Clinical Cancer Research
Molecular Cancer Research
Molecular Cancer Therapeutics

Info for Advertisers
Info for Librarians
Privacy Policy

Twitter
LinkedIn
Facebook
Youtube

Copyright © 2022 by the American Association for Cancer Research.

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.

Accept